Enliven Therapeutics Inc.
ELVN | NASDAQ
$48.35
-$0.52 (-1.06%)
Sep 22, 2026, 2:43 PM ET · Market open
Company Profile
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
Key Executives
| Name | Position |
|---|---|
| Richard A. Fair | CEO, President & Director |
| Anish Patel | Co-Founder & Chief Operating Officer |
| Benjamin Hohl | Chief Financial Officer & Head of Corporate Development |
| Galya D. Blachman | Chief Legal Officer & Head of Business Development |
| Damiette Smit | Vice President of Clinical Development |
| Helen Louise Collins | Chief Medical Officer |
| Joseph Lyssikatos | Co-Founder & Research Fellow |
| Samuel S. Kintz | Co-Founder & Head of Pipeline |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 19, 2026 | 4 | Filing |
| Aug 19, 2026 | 4 | Filing |
| Aug 06, 2026 | 4 | Filing |
| Aug 06, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2026 | 10-Q | Quarterly Report |
| Aug 05, 2026 | 8-K | Current Report |
| Jul 21, 2026 | 4 | Filing |
| Jul 21, 2026 | 4 | Filing |
| Jul 08, 2026 | 4 | Filing |
| Jun 24, 2026 | 4 | Filing |
Enliven Therapeutics Inc.
| Country | United States |
| IPO Date | Mar 11, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 67 |
| CEO | Richard A. Fair |
Contact Details
6200 Lookout Road Boulder,
Colorado 80301 United States
Stock Details
| Ticker Symbol | ELVN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001672619 |
| CUSIP Number | 29337E102 |
| ISIN Number | US29337E1029 |
| SIC Code | 2834 |
Recent News
- 6 days ago / seekingalpha.comEnliven Therapeutics, Inc. (ELVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 19 days ago / prnewswire.comEnliven Therapeutics to Present at Upcoming Investor Conferences
- 19 days ago / seekingalpha.comEnliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing
- 1 month ago / benzinga.comEnliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
- 2 months ago / prnewswire.comEnliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
- 3 months ago / prnewswire.comEnliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
- 3 months ago / gurufocus.comEnliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
- 3 months ago / prnewswire.comEnliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- 3 months ago / seekingalpha.comEnliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid Leukemia Transcript
- 3 months ago / prnewswire.comEnliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
Add to Watchlist
Select watchlists to add or remove ELVN